Loading...
Please wait, while we are loading the content...
Similar Documents
Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study
| Content Provider | Scilit |
|---|---|
| Author | Jorgo, Kliton Polgar, Csaba Stelczer, Gabor Major, Tibor Gesztesi, Laszlo Agoston, Peter |
| Copyright Year | 2021 |
| Abstract | Background: The aim of the study was to evaluate acute side effects after extremely hypofractionated intensity-modulated radiotherapy (IMRT) with stereotactic body radiation therapy (SBRT) for definitive treatment of prostate cancer patients. Patients and methods: Between February 2018 and August 2019, 205 low-, intermediate- and high-risk prostate cancer patients were treated with SBRT using “CyberKnife M6” linear accelerator. In low-risk patients 7.5–8 Gy was delivered to the prostate gland by each fraction. For intermediate- and high-risk disease a dose of 7.5–8 Gy was delivered to the prostate and 6–6.5 Gy to the seminal vesicles by each fraction with a simultaneous integrated boost (SIB) technique. A total of 5 fractions (total dose 37.5–40 Gy) were given on every second working day. Acute radiotherapy-related genitourinary (GU) and gastrointestinal (GI) side effects were assessed using Radiation Therapy Oncology Group (RTOG) scoring system. Results: Of the 205 patients (28 low-, 115 intermediate-, 62 high-risk) treated with SBRT, 203 (99%) completed the radiotherapy as planned. The duration of radiation therapy was 1 week and 3 days. The frequencies of acute radiotherapy-related side effects were as follows: GU grade 0 – 17.1%, grade I – 30.7%, grade II – 50.7%, grade III – 1.5%; and GI grade 0 – 62.4%, grade I–31.7%, grade II–5.9%, grade III–0%. None of the patients developed grade ≥ 4 acute toxicity. Conclusions: SBRT with a total dose of 37.5–40 Gy in 5 fractions appears to be a safe and well tolerated treatment option in patients with prostate cancer, associated with slight or moderate early side effects. Longer follow-up is needed to evaluate long-term toxicity and biochemical control. |
| Related Links | https://www.sciendo.com/pdf/10.2478/raon-2021-0031 |
| Ending Page | 481 |
| Page Count | 8 |
| Starting Page | 474 |
| ISSN | 13182099 |
| e-ISSN | 15813207 |
| DOI | 10.2478/raon-2021-0031 |
| Journal | Radiology and oncology |
| Issue Number | 4 |
| Volume Number | 55 |
| Language | English |
| Publisher | Walter de Gruyter GmbH |
| Publisher Date | 2021-07-13 |
| Access Restriction | Open |
| Subject Keyword | Radiology and Oncology Oncology Cyberknife Extreme Hypofractionation Prostate Cancer Stereotactic Radiotherapy Journal: Radiology and oncology, Issue- 11-12 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Radiology, Nuclear Medicine and Imaging Oncology |
